This systematic review and network meta-analysis updates the efficacy and safety of lebrikizumab, a newly licensed biologic medication for atopic dermatitis, compared to other systemic treatments. The analysis includes 98 trials with 24,707 patients, focusing on efficacy outcomes such as the Eczema Area and Severity Index (EASI), Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), and Peak Pruritus Numeric Rating Scales (PP-NRS). Lebrikizumab showed no significant difference in EASI, POEM, and DLQI scores compared to dupilumab, with high-certainty evidence. However, dupilumab had higher odds of achieving binary efficacy outcomes. Safety outcomes were limited due to low event rates. The study concludes that lebrikizumab is similarly effective to dupilumab for short-term treatment of atopic dermatitis in adults, but dupilumab was more likely to achieve binary efficacy endpoints.This systematic review and network meta-analysis updates the efficacy and safety of lebrikizumab, a newly licensed biologic medication for atopic dermatitis, compared to other systemic treatments. The analysis includes 98 trials with 24,707 patients, focusing on efficacy outcomes such as the Eczema Area and Severity Index (EASI), Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), and Peak Pruritus Numeric Rating Scales (PP-NRS). Lebrikizumab showed no significant difference in EASI, POEM, and DLQI scores compared to dupilumab, with high-certainty evidence. However, dupilumab had higher odds of achieving binary efficacy outcomes. Safety outcomes were limited due to low event rates. The study concludes that lebrikizumab is similarly effective to dupilumab for short-term treatment of atopic dermatitis in adults, but dupilumab was more likely to achieve binary efficacy endpoints.